Background Childhood interstitial lung disease (chILD) encompasses a group of rare heterogeneous respiratory conditions ...
Pulmonary testing is vastly underused but only 15% of those eligible for it get it. Doctors say it could be instrumental in ...
Early intervention for idiopathic pulmonary fibrosis (IPF) is crucial due to the high mortality rate, with emerging therapies like nerandomilast showing potential to reduce health care costs by ...
An experimental therapy, brilaroxazine showed a treatment potential in models of idiopathic pulmonary fibrosis and pulmonary hypertension.
Three distinct pulmonary fibrosis (PF) endotypes were identified, with differing levels of lung function decline and mortality risk.
India.com on MSN1d
Not Just Smoking, 8 Hidden Risks That Could Lead to Lung CancerOur daily habits shape not only our overall health but also the well-being of our lungs. From the food we eat and the level ...
The following is a summary of “Associations between chronic rhinosinusitis and the development of non-cystic fibrosis ...
If you were in the hospital for nearly 100 days, it would probably be very difficult to keep a smile on your face. However, ...
Dr. Frohna covers unmet needs in the latest treatment guidelines and therapies used to combat idiopathic and progressive ...
CUPERTINO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- -Similar patent has also been granted in Japan-Brilaroxazine has received Orphan Drug ...
BOULDER, Colo., May 21, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage ...
Company focused on execution of lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) GRI-0621 interim data readout of Phase 2a biomarker study on track for Q4 2024 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback